Regeneron Pharmaceuticals, Inc. (REGN)
$
579.61
-7.35 (-1.27%)
Key metrics
Financial statements
Free cash flow per share
36.5804
Market cap
61.4 Billion
Price to sales ratio
4.3201
Debt to equity
0.0904
Current ratio
4.5976
Income quality
1.0639
Average inventory
3.2 Billion
ROE
0.1511
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, invention, development, manufacturing, and commercialization of medicines for a range of diseases globally. The operating income ratio is 0.29 indicating the company's operational profitability margin. Its diverse product range includes EYLEA, which is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema, alongside treatments for myopic choroidal neovascularization and various forms of diabetic retinopathy. The company also develops and markets Dupixent for atopic dermatitis and asthma in both adults and children, Libtayo for specific cancers, and Praluent for managing familial hypercholesterolemia and cardiovascular disease. Moreover, REGEN-COV is available for treating COVID-19, while Kevzara addresses rheumatoid arthritis in adults. Regeneron has also made strides in treating Zaire ebolavirus infections through Inmazeb and offers ARCALYST for various periodic syndromes, including familial cold auto-inflammatory syndrome. Furthermore, ZALTRAP is indicated for metastatic colorectal cancer, as the company continually innovates therapies for eye, allergic, inflammatory, cardiovascular, metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions. The net income ratio stands at 0.31 reflecting the company's profitability margin, while the reported income before tax is 4,779,900,000.00 showcasing its pre-tax profitability. Additionally, the earnings per share (EPS) is reported at $40.90 indicating the company's profitability on a per-share basis. The company earned an interest income of $711,400,000.00 showcasing its financial investments. With a large market capitalization of $60,377,973,700.00 Regeneron is a dominant player in the biopharmaceutical industry, contributing significantly to the overall market landscape. The stock is priced at $570.59 positioning it in the higher-end market, and it has an average trading volume of 1,183,998.00 indicating moderate liquidity. As a key player in the Biotechnology industry, Regeneron drives innovation and growth, establishing its presence in the Healthcare sector. The company's collaborative efforts through various agreements with notable partners and institutions further reinforce its strategic positioning and commitment to advancing healthcare solutions.
Is Regeneron Pharmaceuticals, Inc. (REGN) a good investment?
Investing in Regeneron Pharmaceuticals, Inc. (REGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bearish outlook. Always conduct your own research before investing.
What is Regeneron Pharmaceuticals, Inc. (REGN)'s stock forecast?
Analysts predict Regeneron Pharmaceuticals, Inc. stock to fluctuate between $476.49 (low) and $1,192.54 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Regeneron Pharmaceuticals, Inc.'s market capitalization?
As of 2025-08-29, Regeneron Pharmaceuticals, Inc.'s market cap is $60,377,973,700, based on 104,170,000 outstanding shares.
How does Regeneron Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Regeneron Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Regeneron Pharmaceuticals, Inc. pay dividends?
Regeneron Pharmaceuticals, Inc. pays dividends. The current dividend yield is 0.46%, with a payout of $0.88 per share.
How can I buy Regeneron Pharmaceuticals, Inc. (REGN) stock?
To buy Regeneron Pharmaceuticals, Inc. (REGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for REGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Regeneron Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Regeneron Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $14,202,000,000 | EPS: $40.90 | Growth: 10.39%.
Where can I find Regeneron Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.regeneron.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Regeneron Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Regeneron Pharmaceuticals, Inc. stock?
All-time high: $1,211.20 (2024-08-27) | All-time low: $476.49 (2025-06-05).
What are the key trends affecting Regeneron Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
reuters.com
Regeneron Pharmaceuticals said on Tuesday its experimental therapy for treating patients with a rare immune disorder has met the main goal of a late-stage study.
fool.com
Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter has declined 17%.
globenewswire.com
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications.
zacks.com
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
seekingalpha.com
Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic moves in obesity drugs aim for future growth.
benzinga.com
On Friday, Regeneron Pharmaceuticals Inc. REGN reported upbeat second-quarter earnings.
fool.com
The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.
seekingalpha.com
Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming approvals should be more than sufficient to keep Regeneron in growth mode. The obesity pipeline expansion adds a new growth avenue for the company in the 2030s.
seekingalpha.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO George D.
See all news
